Login
Navigate Fool.com
Will ATRS beat
the market?

Antares Pharma, Inc. (NASDAQ: ATRS)

Community Rating: 3 Stars: Appealing

2.23 -0.06 (-2.62%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.30
Previous Close $2.29
Daily Range $2.23 - $2.30
52-Week Range $2.04 - $5.15
Market Cap $289.9M
P/E Ratio -11.45
Dividend (Yield) $0.00 (0.0%)
Volume 853,139
Average Daily Volume 1,410,298
Current FY EPS -$0.24

How do you think ATRS
will perform against the market?

Top ATRS Bull/Bear Pitches

 

bruceedge (0)
Submitted June 19, 2011

interesting product line addressing some large markets and very strong technical chart with insider buying

1 Replies Reply Report this Post
 

EclecticRecluse (< 20)
Submitted October 26, 2010

Extremely High Price for Sales

0 Replies Reply Report this Post

News & Commentary

3 Stocks Crushed by the Market This Week

Find out which health-care stocks got beaten down the most by the market over the past few days.

Why Antares Pharma Inc. Shares Dove

Antares shares go off track following the resignation of its CEO. Find out if this is something investors should be genuinely concerned about or if it's a short-term event.

Healthcare Stocks Ending With Losses; Antares Pharma Sues to Protect Arthritis Drug Patent

Sector Update: Healthcare

Today's Biggest Biotech Stories: Antares Pharma Inc., BioCryst Pharmaceuticals Inc., and Raptor Phar

Today's movers in biotech.

Sector Update: Healthcare Shares Mixed Pre-Market; Antares Pharma's OTREXUP Released

Sector Update: Healthcare

3 Disruptive Medical Innovations You Can Invest In

3-D-printed organs, needle-free injectors, and inhalable insulin -- these three disruptive medical innovations that are being brought to the market respectively by Organovo, Antares Pharma, and MannKind.

This Week in Biotech

Two Food and Drug Administration drug approvals, a cholesterol-lowering drug impresses in a big way, and two biotechs getting slaughtered following a disappointing clinical update are this week's top biotech stories.

Is This New Rheumatoid Arthritis Treatment a Game Changer?

Antares Pharma just patented a self-injectable version of a widely available generic drug. Can this new treatment decrease the company’s dependence on its larger generic customers?

See More ATRS News...

Sector

Healthcare

Industry

Healthcare Information Services

Antares Pharma, Inc. (ATRS) Description

The Company develops, produces and markets pharmaceutical delivery products, including transdermal gels, oral fast melting tablets and reusable needle-free and disposable mini-needle injector systems. Website: http://www.antarespharma.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks